BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38174993)

  • 1. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance.
    Zhang X; Lao M; Yang H; Sun K; Dong Y; He L; Jiang X; Wu H; Jiang Y; Li M; Ying H; Liu X; Xu J; Chen Y; Zhang H; Zhou R; Gao J; Bai X; Liang T
    Autophagy; 2024 Jun; 20(6):1314-1334. PubMed ID: 38174993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
    Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
    Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
    Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
    Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
    Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
    Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
    Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
    Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis.
    Parte S; Kaur AB; Nimmakayala RK; Ogunleye AO; Chirravuri R; Vengoji R; Leon F; Nallasamy P; Rauth S; Alsafwani ZW; Lele S; Cox JL; Bhat I; Singh S; Batra SK; Ponnusamy MP
    Gastroenterology; 2024 May; 166(5):842-858.e5. PubMed ID: 38154529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
    Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
    Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC.
    Musiu C; Lupo F; Agostini A; Lionetto G; Bevere M; Paiella S; Carbone C; Corbo V; Ugel S; De Sanctis F
    Front Immunol; 2024; 15():1341079. PubMed ID: 38817612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities.
    Qin Q; Yu R; Eriksson JE; Tsai HI; Zhu H
    Cancer Lett; 2024 Jun; 591():216859. PubMed ID: 38615928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
    Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
    Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy loss impedes cancer-associated fibroblast activation via downregulating proline biosynthesis.
    Bai J; Liu T; Tu B; Yuan M; Shu Z; Fan M; Huo S; Guo Y; Wang L; Wang H; Zhao Y
    Autophagy; 2023 Feb; 19(2):632-643. PubMed ID: 35786294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
    Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
    Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
    Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
    Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
    Stouten I; van Montfoort N; Hawinkels LJAC
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.